-
Something wrong with this record ?
Aktuality z odborného tisku
Články vybral a komentoval: MUDr. Peter Grell, Ph.D.
Status not-indexed Language Czech Country Czech Republic
Document type Overall
EV-302/ KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/ mUC) -- First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion–positive NSCLC -- Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/ IDEA pooled analysis of seven trials -- Pyrotinib vs. placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23023113
- 003
- CZ-PrNML
- 005
- 20240318151004.0
- 007
- ta
- 008
- 240109s2023 xr f 000 0|cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a cze
- 044 __
- $a xr
- 100 1_
- $a Grell, Peter $7 xx0107816 $u Klinika komplexní onkologické péče LF MU a MOÚ Brno
- 245 10
- $a Aktuality z odborného tisku / $c Články vybral a komentoval: MUDr. Peter Grell, Ph.D.
- 505 0_
- $a EV-302/ KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/ mUC) -- First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion–positive NSCLC -- Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/ IDEA pooled analysis of seven trials -- Pyrotinib vs. placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
- 590 __
- $a NEINDEXOVÁNO
- 655 _7
- $a souhrny $7 D016424 $2 czmesh
- 773 0_
- $w MED00011030 $t Klinická onkologie $x 0862-495X $g Roč. 36, č. 6 (2023), s. 481-483
- 856 41
- $u https://www.prolekare.cz/casopisy/klinicka-onkologie/2023-6-5/ohlednuti-za-13-kongresem-psogi-je-neco-noveho-v-lecbe-peritonealnich-malignit-136067 $y plný text volně dostupný
- 910 __
- $a ABA008 $b B 1665 $c 656 $y p $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240318151001 $b ABA008
- 999 __
- $a ok $b bmc $g 2065231 $s 1209563
- BAS __
- $a 6
- BAS __
- $a PreBMC
- BMC __
- $a 2023 $b 36 $c 6 $d 481-483 $i 0862-495X $m Klinická onkologie $x MED00011030 $y 136067
- LZP __
- $b NLK111 $a Meditorial-20240109
